Integra Lifesciences Holdings (IART) Convertible Debt (2009 - 2026)

Integra Lifesciences Holdings' Convertible Debt history runs 17 years deep, the most recent figure standing at $76.4 million for Q1 2026.

• In Q1 2026, Convertible Debt fell 25.17% year-over-year to $76.4 million; the TTM figure through Mar 2026 stood at $76.4 million (down 25.17% YoY), while the FY2024 annual figure was $108.1 million, up 21.19% from the prior year.
• Convertible Debt came in at $76.4 million for Q1 2026 at Integra Lifesciences Holdings, down from $83.5 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $569.5 million in Q3 2023 to a low of $76.4 million in Q1 2026.
• A 5-year average of $222.8 million and a median of $108.1 million in 2024 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt surged 407.2% in 2023 and plunged 86.34% in 2024, its largest moves.
• Integra Lifesciences Holdings' Convertible Debt stood at $104.7 million in 2022, then declined by 14.8% to $89.2 million in 2023, then increased by 21.19% to $108.1 million in 2024, then decreased by 22.76% to $83.5 million in 2025, then dropped by 8.5% to $76.4 million in 2026.
• According to Business Quant data, Convertible Debt over the past three periods registered $76.4 million, $83.5 million, and $108.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.

Peer Comparison